Last reviewed · How we verify
Bupivacaine Hcl 0.75% Inj
Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.
Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.
At a glance
| Generic name | Bupivacaine Hcl 0.75% Inj |
|---|---|
| Sponsor | Rothman Institute Orthopaedics |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Bupivacaine reversibly binds to and inactivates voltage-gated sodium channels on the inner surface of nerve cell membranes, thereby preventing depolarization and action potential propagation. This results in a loss of sensation in the infiltrated tissue. The drug has a relatively long duration of action compared to other local anesthetics due to its high lipophilicity and protein binding.
Approved indications
- Local and regional anesthesia for surgical procedures
- Infiltration anesthesia
- Nerve blocks
- Epidural anesthesia
Common side effects
- Systemic toxicity (CNS effects: tremor, seizures)
- Cardiovascular effects (hypotension, arrhythmias)
- Local reactions at injection site
- Allergic reactions
Key clinical trials
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
- Exparel v Dexamethasone in RCR (PHASE4)
- Liposomal Bupivacaine With Dexamethasone for Foot Surgery (PHASE4)
- Evaluation of Duration of Anesthesia and Patient Satisfaction After Retrobulbar Block Applied in Cataract Surgery
- Epidural Volume Extension and Intrathecal Use of Local Anesthetics in Cesarean Sections (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine Hcl 0.75% Inj CI brief — competitive landscape report
- Bupivacaine Hcl 0.75% Inj updates RSS · CI watch RSS
- Rothman Institute Orthopaedics portfolio CI